: Clotting Cascade and New Oral Anticoagulants 10 i. New oral anticoagulants (NOACs) versus warfarin therapy 11 1. Reduction in intracranial hemorrhage 2. Bleeding rates similar or lower (0. 12 1. Statistically significant higher bleeding rates for life-threatening bleeding and minor bleeding in warfarin group versus dabigatran 2. Statistically significant higher bleeding rates for gastrointestinal bleeding in dabigatran group versus warfarin 3. No significant difference between bleeding rates for intracranial hemorrhage or major bleeding in dabigatran group versus warfarin ii. Apixaban 13 1. Statistically significant lower rates of major bleeding, intracranial bleeding, and any bleeding in apixaban group compared to warfarin 2. No statistical difference between gastrointestinal bleeding rates in the apixaban group compared to warfarin iii. Rivaroxaban 14 1. No statistically significant difference between rivaroxaban and enoxaparin/warfarin bleeding rates 
0.77
Major bleeding: decrease hemoglobin ≥2 gm/dL and/or transfusion ≥2 units blood or both, bleeding in a critical site, contributing to death 2. Proposed mechanism of NOAC reversal: large amounts of factor X may decrease inhibitory effects of factor Xa inhibitors; may overcome factor Xa inhibition by increasing thrombin generation 20 3. Only 2 available in the US (Bebulin VH and Profilnine SD) 4. 3F-PCC less likely to increase thrombosis than 4F-PCC a. 0.7% reported incidence of thromboembolic events with 3F-PCC versus 1.8% in 4F-PCC in reversal of warfarin 21 5. Warning: risk of transmitting infectious agents is possible 6. Bebulin VH: factor IX complex nanofiltered and vapor heated 21 a. Indication: control/prevention of bleeding episodes in adults with hemophilia B (congenital factor IX deficiency) b. Contains factor II, IX, X, low amounts of factor VII and heparin c. Contraindications: allergy to heparin, history of HIT (heparin induced thrombocytopenia) d. Adverse effects: hypotension, dizziness, urticaria, erythema, pyrexia, chills, DVT, PE, stroke, disseminated intravascular coagulation (DIC) 7. Profilnine SD: factor IX complex solvent detergent treated 22 a. Indication: control and prevention of bleeding in factor IX deficient patients due to hemophilia B b. Contains factor II, IX, X, and low levels factor VII c. Adverse effects: urticaria, nausea, vomiting, headache, fever, chills, somnolence, thrombosis, DIC i. "Infrequent but consistent reports have been described which indicate that patients are at greater risk of developing thrombosis" 22 iii. 4-factor prothrombin complex concentrates (4F-PCC) 16 1. Similar concentrations of factors II, VII, IX, and X a. Contains higher concentrations of factor VII compared to 3F-PCCs b. Some formulations contain additional coagulants c. Available in activated and nonactivated factor VII 2. Warning: risk of transmitting infectious agents is possible 3. Kcentra 16, 23 a. Non-activated 4F-PCC contains 25 times more concentrated coagulation factors than found in the plasma b. Indication: urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist in acute major bleeding or need for urgent surgery/invasive procedure c. Contains factors II, VII, IX, X, proteins C and S, antithrombin III d. Dose: based on INR values and weight e. Mechanism of action: rapidly increases plasma levels of vitamin K-dependent coagulation factor II, VII, IX, and X and proteins C/S f. Contraindicated: DIC, HIT g. Adverse effects:
i. Glanzmann's thrombasthenia with refractoriness to platelet transfusions b. Contains activated factor VII c. Mechanism of action: after complexing with tissue factor (TF), activated coagulation factor X to factor Xa and factor IX to factor IXa; factor Xa then converts prothrombin to thrombin and forms a hemostatic plug via the conversion of fibrinogen to fibrin d. Adverse effects: thrombosis, bleeding i. Black box warning: can cause arterial and venous thrombotic events ii. 4% occurrence of thromboembolic events (cerebral artery occlusion, cerebral ischemia, angina pectoris, myocardial infarction, PE, DVT) a. Serious reported adverse effects: 1 case of pneumonia b. Administration of andexanet alfa IV bolus followed by a 2 hour continuous infusion after the administration of apixaban produced a rapid, nearly complete, and sustained reversal of the anticoagulant effect c. Ongoing phase 2 proof-of-concept study interim results for 6 day treatment with apixaban 5 mg twice daily (n=6), after a 420 mg bolus andexanet alfa; anticoagulant reversal of apixaban was 92% (p<0.0001) compared to placebo (n=3), and after the two hour infusion, reversal was 91% (p<0.0001) d. 210 mg and 420 mg of andexanet alfa reversed rivaroxaban's anticoagulant effects (20 mg daily) by 32% and 51% after 2 minutes, respectively ii. PER977 31 1. Synthetic small molecule antidote for potential reversal of apixaban, rivaroxaban, dabigatran, fondaparinux, low molecular weight heparin 2. Demonstrated ex vivo reversal of apixaban and rivaroxaban when analyzing aPTT and anti-Xa levels iii. aDabi-Fab 32 1. Antibody fragment for reversal of dabigatran 2. Mimics thrombin, high affinity for dabigatran 3. Reversed dabigatran clotting time in an in vivo rat model V.
Evidence for Reversal of New Oral Anticoagulant increased above baseline at higher PCC concentrations (n=7); slightly increased ETP at higher rivaroxaban concentrations  aPCC: significantly increased ETP above baseline in 200 ng/mL rivaroxaban and significantly reversed rivaroxaban 500 ng/mL at 0.4 U/mL (P<0.01 vs rivaroxaban, n=5); slight increase of ETP in rivaroxaban 1000 ng/mL at 0.4 U/mL and above (P<0.01 vs. rivaroxaban) significantly increased Cmax of rivaroxaban 500 ng/mL at doses above 5 μg/mL rFVIIa (P<0.01 vs. rivaroxaban) and rivaroxaban 1000 ng/mL at 50 μg/mL rFVIIa (P<0.01 vs rivaroxaban, n=6-8)  aPCC and rFVIIa partially reversed inhibition of Cmax Authors' Conclusions  All agents were partially effective for reversal of rivaroxaban-induced anticoagulation  rFVIIa and aPCC were more effective than PCC in reversal of PT, CT, lag time of TG Comments Strengths  Compared multiple reversal agents at different doses  Simulated therapeutic and overdose concentrations of rivaroxaban Limitations  Clot based assays may not predict reversal potential of agents  In vitro study  Agent availability and application in the U.S.
Table 9: Escolar G, Fernandez-Gallego, Arellano-Rodrigo E, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro
with circulating human blood. Plos ONE. 2013;8(11):e78696. 34 
Purpose
To investigate the effects of apixaban on platelets and hemostasis in humans and determine the effectiveness of different factor concentrations at reversing apixaban's effects on hemostasis Design
In vitro study design Inclusion  Healthy volunteers Exclusion  Patients using acetylsalicylic acid, non-steroidal anti-inflammatory or antiplatelet drugs within the past 7 days Outcomes
Clotting assays, measure TG, clot formation time (CFT) and maximum clot firmness (MCF) as well as thrombin peak, lag phase, and time peak to determine reversal of apixaban and determine effects in damaged vasculature (see Appendix D, pg 20) Methods  Blood samples were donated and apixaban was added to the samples at a concentration of 200 ng/mL, twice the average Cmax achieved in patients' receiving dosages for atrial fibrillation  The following coagulation factor concentrates were tested on apixaban:
o rFVIIa (Novoseven) 270 μg/kg o aPCC (FEIBA) 75 U/kg o 4F-PCC (Beriplex) 50 IU/kg (similar to 4F-PCC Kcentra)  Assumed a patient's weight was ~70kg  Used whole blood samples to analyze clot formation for 45 minutes  Coagulation factor concentrates were tested in blood samples and reversal of anticoagulant effect was analyzed via clotting assays  Blood was perfused through rabbit aortas to analyze changes when exposed to damaged vascular components Statistics ANOVA and Wilcoxon-Mann-Whitney test for Gaussian distribution 56.9± 1.6# *P<0.01 vs control; **P<0.01 vs apixaban; #P<0.05 vs apixaban; CON:control; Apix:apixaban  rFVIIa and aPCC significantly normalized the prolongation to reach peak TG  rFVIIa and aPCC significantly reversed lag phase and thrombin peak  rFVIIa and aPCCs significantly reduced prolongation of CT and CFT  Apixaban: apixaban reduced fibrin formation/platelet interaction in damaged vessels o aPCCs, PCCs, and rFVIIa returned fibrin levels to baseline rFVIIa partially reversed apixaban's effects on platelet interactions Authors' Conclusions  aPCC shows a potential for apixaban reversal  aPCC may be a first line reversal agent for apixaban  Do not recommend rFVIIa due to thrombogenicity, especially with off label use  Results may vary based on specific assays Comments Strengths  Examined apixaban concentrations with twice the average Cmax in patients on therapeutic doses of apixaban Limitations  In vitro design limits applicability of study conclusions  Short time period for collecting data and availability of agents  Rabbit aorta used to study damaged tissue may lead to different conclusions N=10 Rivaroxaban ETP  PCC: dose dependent increase in ETP (37% with 0.25 U/mL PCC); only dose that reversed ETP to near baseline; overcorrection by higher concentrations  aPCC: dose dependent increase in ETP (50% increase for 0.25 U/mL p<0.001, only dose that reversed it to near baseline); overcorrection by higher concentrations  rFVIIa: no correction of ETP Thrombin peak  PCC: dose dependent correction  aPCC: dose dependent correction; 1 and 2 U/mL corrected peak close to baseline (P=0.02)  rFVIIa: reduced peak (P=0.02) Lag time  PCC: small reduction in lag time (15%)  aPCC: significant reduction (47%, P<0.0001, rate of thrombin increased to >25 nM/min but did not reach baseline rate)  rFVIIa: complete reversal of lag time to baseline (P<0.001, rate of thrombin increased to >25 nM/min but did not reach baseline rate) Time to reach maximum concentration of thrombin  PCC: no effect  aPCC: decreased time to peak concentration by 30% (p<0.001); increased rate of thrombin formation but did not reach baseline  rFVIIa: decreased time to peak concentration by 44% (P<0.001); increased rate of thrombin formation but did not reach baseline Dabigatran ETP  PCC: dose dependent increase in ETP; reached baseline at lowest dose (P=0.02)  aPCC: dose dependent increase in ETP; reached baseline at lowest dose (P=0.02)  rFVIIa: no correction of ETP Thrombin peak  PCC: increased thrombin peak above baseline at lowest dose (P<0.001)  aPCC: increased thrombin peak above baseline at lowest dose (P<0.001)  rFVIIa: did not increase thrombin peak above baseline Lag time  PCC: no significant correction of lag time  aPCC: all doses except 0.25 U/mL reduced lag time (P<0.001)  rFVIIa: highest dose significantly decreased lag time (P<0.001) Time to reach maximum concentration of thrombin  PCC: no effect  aPCC: significantly reduced by lowest dose of aPCC (P=0.03) close to baseline  rFVIIa: reduced time to reach maximum concentration Authors' Conclusions  aPCC combines the reversal effects of PCC and rFVIIa to correct both lag time and peak  aPCC is the most reasonable theoretical option for reversal of rivaroxaban  Animal models do not provide evidence for use of rFVIIa  aPCC may be useful for dabigatran dosing, but the dose needs to be determined Comments Strengths  Randomized, placebo controlled trial Limitations  Ex vivo study design limits applicability of study conclusions  Duration or response not assessed (short half-lives of reversal agents)  Assessed one dose of anticoagulant; availability of agent; no active bleeding Time from the addition of calcium to formation of a fibrin clot Linear response to dabigatran up to therapeutic dose (not quantitative in overdose)
Anti-Xa
Measures the change in absorbance of specific clotting factor Xa activity
Monitoring factor Xa inhibitors (if calibration and appropriate control agent available)
Clot formation time (CFT)
Speed of clot formation from 2 mm to 20 mm above baseline in seconds Prolonged by apixaban
Clotting time (CT)
Measures conversion of fibrinogen to fibrin (time until clot reaches 2 mm)
May be useful for dabigatran to steady-state levels; increased by rivaroxaban and apixaban Hemoglobin/hematocrit and platelets (bleeding), creatinine clearance (renal function) Coagulation assays and effect on patient outcomes not established; different reagents used in laboratory settings have different responsiveness
